Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD40 ligation for immunotherapy of solid tumours.

S M Todryk1, A L Tutt, M H Green

  • 1Division of Oncology, St. George's Hospital Medical School, Cranmer Terrace, SW17 0RE, London, UK .

Journal of Immunological Methods
|February 27, 2001
PubMed
Summary

Anti-CD40 monoclonal antibody (mAb) therapy effectively treats solid tumours by stimulating antigen-presenting cells (APCs) to activate cytotoxic T lymphocytes (CTLs), bypassing the need for T helper cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vivo kinetics of oleic, linoleic, and α-linolenic acid biohydrogenation in the rumen of dairy cows.

Journal of dairy science·2022
Same author

Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2020
Same author

Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.

Oncoimmunology·2018
Same author

Corrigendum to "Technical note: An in vivo method to determine kinetics of unsaturated fatty acid biohydrogenation in the rumen" (J. Dairy Sci. 101:4259-4267).

Journal of dairy science·2018
Same author

Technical note: An in vivo method to determine kinetics of unsaturated fatty acid biohydrogenation in the rumen.

Journal of dairy science·2018
Same author

The T4 molecule: function and structure.

Immunology today·2014

Area of Science:

  • Immunology
  • Cancer Research
  • Therapeutics

Background:

  • T-cell responses to tumours are often weak and ineffective.
  • T helper (Th) cells are crucial for stimulating antigen-presenting cells (APCs) via CD40-CD154 interaction.
  • Inadequate Th-cell responses can impair cytotoxic T lymphocyte (CTL) priming against tumours.

Purpose of the Study:

  • To investigate the efficacy of anti-CD40 monoclonal antibody (mAb) therapy in treating solid tumours.
  • To determine if anti-CD40 mAb can overcome limitations in Th-cell responses for effective anti-tumour immunity.

Main Methods:

  • Administration of anti-CD40 mAb to mice bearing solid tumours.
  • Assessment of tumour response, including immunogenicity and aggressiveness.
  • Evaluation of T-cell involvement through cytokine production (interferon-gamma) and CTL activity.

Related Experiment Videos

  • Studies using nude mice (lacking T-cells) and CD4(+) or CD8(+) cell depletion.

    • Main Results:

    • Anti-CD40 mAb therapy was effective against CD40-negative solid tumours.
    • Treatment efficacy correlated with tumour immunogenicity and aggressiveness.
    • Therapeutic effects required T-cells, evidenced by interferon-gamma production and CTL activity.
    • Depletion of CD8(+) cells abrogated protection, while CD4(+) cell depletion had no effect.
    • The response bypassed the requirement for Th cells.

    Conclusions:

    • Solid CD40-negative tumours are sensitive to anti-CD40 mAb therapy.
    • This therapy can generate effective anti-tumour immunity by stimulating APCs to prime CTLs.
    • The mechanism of action bypasses the need for T helper cell involvement, offering a potential therapeutic strategy.